Pfizer Takes A Hit On US Oncology Biosimilars In Q1

Lower Net Prices Take A Bite Out Of Firm’s First-Quarter Biosimilars Turnover

 
• By Dave Wallace
  
Pfizer logo next to syringe
Pfizer saw its US oncology biosimilars sales drop by 47% in Q1 • Source: Shutterstock

More from Earnings

More from Business